Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNN targeting siRNA
- Development stage
- Preclinical
- Lead developer
- NurExone Biologic
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
NurExone Biologic is developing a small interfering RNA (siRNA) therapy designed to target the perineuronal net (PNN) for the treatment of facial nerve injury. The PNN is a specialized extracellular matrix that stabilizes synapses but also restricts neural plasticity and regeneration after trauma. By utilizing siRNA to knockdown key components of the PNN, such as chondroitin sulfate proteoglycans (CSPGs), the treatment aims to dismantle these inhibitory structures and facilitate axonal regrowth and functional repair. This program leverages NurExone's proprietary ExoTherapy platform, which uses modified exosomes to deliver molecular cargoes directly to damaged nerve tissues.
- Other names
- NurExone Biologic-PNN (Perineuronal Net)-siRNAPNN-siRNA
02
Targets
CSPG (Chondroitin sulfate proteoglycan)
Beyond the preview
Go deeper on PNN targeting siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNN targeting siRNA.